Homburger advised Molecular Partners AG in connection with its Initial Public Offering in the United States and listing on NASDAQ

June 18, 2021. Homburger advised Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, in connection with its Initial Public Offering of 3,000,000 American Depositary Shares in the United States at a public offering price of USD 21.25 per ADS, for total gross proceeds of approximately USD 63.8 m. Each ADS represents one new ordinary share issued by Molecular Partners out of its authorized share capital. Trading of the ADSs commenced on the Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol “MOLN.” Molecular Partner’s ordinary shares continue to be listed and traded on SIX Swiss Exchange making the stock dual listed.

J.P. Morgan, SVB Leerink and Cowen acted as joint book-running managers for the offering. RBC Capital Markets acted as the bookrunner, Kempen & Co as the lead manager for the offering.

Molecular Partners was advised by Homburger in this transaction. The Homburger team was led by partner Dieter Gericke (Corporate / M&A, Capital Markets) and included partner Stefan Oesterhelt (Tax) as well as associates Lorenzo Togni, Karin Mattle and Francesco Bernasconi (all Corporate / M&A, Capital Markets) and junior associate Tanja Niederer (Corporate / M&A, Capital Markets).